Molecular Imaging
Articles tagged with Molecular Imaging
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: May 4, 2026
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
Novel theranostic approach for radioimmunotherapy achieves curative responses in colorectal cancer tumors
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
Double-slit experiment reveals hidden details between light and matter
Scientists successfully built the smallest X-ray interferometer to measure how X-rays interact with atomic nuclei. This breakthrough technology enables precise measurement of X-ray refraction and provides new avenues for research.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 23, 2026
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
PET biomarker outperforms established risk score in predicting survival for large B-cell lymphoma patients
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
How can scientists visualize cellular life with greater precision?
Salk scientists and collaborators advance visualization technology using visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs), reducing background fluorescence by up to a hundredfold. The new probe enables high spatial and temporal precision, allowing for real-time tracking of dynamic changes in living models.
SNMMI annual meeting to take place May 30-June 2, 2026
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 10, 2026
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
New optical-coupled scanning probe microscope sees atoms and molecules without liquid helium
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 3, 2026
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 27, 2026
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Anil Parsram Bidkar, PhD, receives SNMMI-PCF Young Investigator's Award
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai, PhD, receives SNMMI Mars Shot Research Fund Award
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
Chun Li, PhD, receives SNMMI Mars Shot Research Fund Award
Dr. Chun Li has been awarded the SNMMI Mars Shot Research Fund Award to investigate the PET radiotracer 64Cu-DbCD11b for detecting vulnerable atherosclerotic plaques. The study aims to assess the non-invasive assessment of vulnerable plaques and aid in patient risk identification and treatment.
David H. Ballard, MD, receives SNMMI Mars Shot Research Fund Award
Dr. David H. Ballard, MD, has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop novel PET/MR imaging techniques for metabolic activity and inflammation in Crohn's disease. The study aims to improve biologically informed decision-making and guide treatment decisions.
Ansel Hillmer, PhD, and Eric Webb, PhD, receives SNMMI Mars Shot Research Fund Award
Researchers Ansel Hillmer and Eric Webb have received the $100,000 Drs. Jane & Abass Alavi Mars Shot Research Award to advance imaging research in infection and inflammation for Alzheimer's disease. They aim to develop a PET radiotracer targeting CSF1R to diagnose and monitor brain inflammation.
Carolyn J. Anderson, PhD, receives SNMMI Mars Shot Research Fund Award
Dr. Carolyn J. Anderson has been awarded a $100,000 grant from the SNMMI Mars Shot Research Fund to develop a PET radiotracer for imaging vaso-occlusive crisis in sickle cell disease. The award will support the production and validation of an easy-to-produce and high-yielding PET radiotracer, 18F-LLP2A, for rapid translation to patients.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 20, 2026
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Arvin Haj-Mirzaian, MD, and Pedram Heidari, MD, receive SNMMI Mars Shot Research Fund Award
Researchers Haj-Mirzaian and Heidari aim to develop non-invasive imaging biomarker <sup> 18 </sup> F-NaF PET/CT for early calciphylaxis diagnosis in dialysis-dependent patients. This could lead to timely interventions, reduced mortality, and improved patient outcomes.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 6, 2026
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
The Journal of Nuclear Medicine ahead-of-print tip sheet: February 27, 2026
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
Targeted PET/CT predicts early treatment response in rheumatoid arthritis patients
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
Quantitative FDG PET and MRI framework detects emerging form of dementia, "LATE"
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
The Journal of Nuclear Medicine ahead-of-print tip sheet: February 20, 2026
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
Hearing a molecule’s solo performance
Scientists have created a way to hear a single molecule 'sing' using infrared-integrated STM. This technique combines infrared excitation with scanning tunneling microscopy, allowing for the detection of individual molecular vibrations.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 13, 2026
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann to be next Editor-in-Chief of The Journal of Nuclear Medicine
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
University of Missouri conducts first in-person clinical trial for nuclear medicine breakthrough device
The University of Missouri has launched its first human clinical trial using Eye90 microspheres, a radiopharmaceutical breakthrough device manufactured on campus. The study aims to assess the safety and effectiveness of Eye90 in treating unresectable liver tumors, including hepatocellular carcinoma and metastatic colorectal cancer.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 6, 2026
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 2, 2026
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
Novel combined PET imaging approach personalizes treatment for head and neck cancer
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
Bringing optical color to ultrasound
Scientists have developed a new technique that combines rotational ultrasound tomography (RUST) with photoacoustic tomography (PAT) to create 3D color images of soft tissues and blood vessel function. This method has the potential to enhance breast tumor imaging, monitor nerve damage caused by diabetes, and brain imaging.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
The Journal of Nuclear Medicine ahead-of-print tip sheet: January 16, 2026
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
Novel theranostic model shows curative potential for gastric and pancreatic tumors
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
IIT: a new microscopy technique that preserves the cell’s natural conditions
Researchers at IIT develop optical microscopy technique that combines polarization and dark-field microscopy to observe cells with high contrast, preserving their natural conditions. The next step involves using AI to enrich images with molecular information related to diseases.
The Journal of Nuclear Medicine ahead-of-print tip sheet: Jan. 9, 2026
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 2, 2026
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
Deep-learning model predicts how fruit flies form, cell by cell
A team of MIT engineers developed a deep-learning model that predicts how individual cells will fold, divide, and rearrange during a fruit fly's earliest stage of growth. The model achieved 90% accuracy in predicting the movement of 5,000 cells over the first hour of development.
The Journal of Nuclear Medicine ahead-of-print tip sheet: December 12, 2025
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
Researchers developed multimodal models integrating imaging, clinical, and molecular data from TAILORx tissue biorepository for early-stage breast cancer. The models demonstrated enhanced prognostic performance compared to existing methods, highlighting their potential for personalized treatment decision-making.
Journal of Nuclear Medicine Technology supplement highlights advances in theranostics and opportunities for growth
This supplement highlights key areas of focus for theranostics, including clinical lessons, education, science, multidisciplinary collaboration, and equity. It also explores new frontiers beyond oncology and examines finance, sustainability, policy, strategy, and future directions.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: December 5, 2025
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 21, 2025
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 14, 2025
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
Rapid growth of radiopharmaceutical therapy highlights need for expertise
The Society of Nuclear Medicine and Molecular Imaging emphasizes the importance of education, training, and experience for safe and effective delivery of radiopharmaceutical therapy. Specialized expertise is needed to handle radioactive compounds and ensure patient safety.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 7, 2025
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model
A new radioimmunotherapy approach has been developed to treat HER2-positive breast cancer, resulting in complete and histologic cures with minimal toxicities. The treatment uses a pretargeted approach to directly target tumors, reducing the risk of radiation toxicity to healthy tissues.
Australian scientists uncover secrets of yellow fever
Researchers at the University of Queensland have captured high-resolution images of the yellow fever virus, shedding light on its structural differences between the vaccine strain and disease-causing variants. The study reveals that these differences impact how the immune system recognizes the virus.
Photoactivatable molecular tag illuminates life inside living cells
Researchers from The University of Osaka and The University of Tokyo have developed a novel technology that visualizes specific molecules inside living cells using light. The new photo-responsive alkyne tag enables precise visualization without disrupting molecular dynamics.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 24, 2025
Researchers have developed a new PET imaging agent that can distinguish true tumor response from inflammation during immune checkpoint inhibitor therapy. This breakthrough has the potential to improve early treatment assessment and patient outcomes.
PET imaging of inflammation predicts recovery, guides therapy after heart attack
A new approach to PET imaging can identify patients at risk of poor functional recovery after a heart attack by visualizing CXCR4, a cellular protein involved in inflammation. This technique enables timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 17, 2025
Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...
NUH and NUS launch new Molecular Imaging and Theranostics Centre to strengthen patient care and research
The new Molecular Imaging and Theranostics Centre at NUH and NUS Medicine enables faster, safer and more precise diagnoses, while researchers can observe real-time tracer movement throughout the body. This opens possibilities for validating next-generation diagnostics and therapies, advancing theranostics.
High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment
Researchers developed a high-speed whole-body SPECT method to track tumor evolution and personalize prostate cancer treatment. The new approach enabled faster monitoring, allowing for earlier adjustments to treatment plans and improved patient outcomes.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 10, 2025
Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 6, 2025
Recent studies published in The Journal of Nuclear Medicine have made significant breakthroughs in prostate cancer treatment, with multiple therapies showing promise. Researchers have also discovered ways to reduce radiation exposure in PET scans and tracked the effects of alpha therapy on patients.
Startling images show how antibiotic pierces bacteria’s armor
Researchers from UCL and Imperial College London have discovered how life-saving antibiotics called polymyxins target the outer layer of Gram-negative bacteria. By triggering the production and shedding of this armor, polymyxins create gaps in the cell's defenses, allowing the antibiotic to enter and kill the bacteria.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 26, 2025
Researchers have developed promising therapies for advanced prostate cancer, improved brain imaging capabilities, and enhanced liver cancer detection. A new alpha therapy shows promise in treating thyroid cancer, while AI-assisted tracking systems enhance prognosis prediction in prostate cancer imaging.